IOVA
HealthcareIovance Biotherapeutics, Inc.
$2.45
$-0.07 (-2.78%)
Jan 5, 2026
Price History (1Y)
Analysis
Iovance Biotherapeutics, Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $972.57 million and annual revenues of $250.42 million. It employs 838 individuals. The company's financial health is marked by significant losses, with a net income of -$397,632,992 and EBITDA of -$375,784,992 over the trailing twelve months. The operating margin stands at -133.1%, while the profit margin is -158.8%. Returns on equity and assets are also negative, at -53.9% and -27.1%, respectively. The company's balance sheet shows $300.80 million in cash and $52.49 million in debt, resulting in a debt to equity ratio of 7.47. Valuation metrics for the company include a forward P/E ratio of -4.01 and an EV/EBITDA ratio of -2.00. The revenue growth rate is 15.2% year-over-year, while earnings growth is not available due to negative net income.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Visit website →Key Statistics
- Market Cap
- $972.57M
- P/E Ratio
- N/A
- 52-Week High
- $7.69
- 52-Week Low
- $1.64
- Avg Volume
- 14.62M
- Beta
- 0.77
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 838